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END-OF-LIFE CARE IN HEMATOLOGY AND STEM CELL TRANSPLANT
PATIENTS AND EVALUATION OF A HEMATOLOGY-QUALITY OF DYING
ASSESSMENT (H-QODA)
Rowlings, P.1,2, Zhang, H.1, Rohr, Y.3 1Newcastle Mater Hospital &
HAPS, Waratah, Newcastle, NSW, Australia; 2HMRI & Newcastle
University, Newcastle, NSW, Australia; 3Division of Palliative Care,
Newcastle Mater Hospital, Waratah, Newcastle, NSW, Australia.
Background: Improving quality of end-of-life (EOL) care be-
comes the highest priority when prolonging survival is no longer
possible. To identify factors impacting EOL care, we retrospec-
tively studied patients (pts) dying over 12 months managed by a
single unit. We also evaluated a Hematology-Quality of Dying
Assessment (H-QODA), modiﬁed from a QODA proposed for pts
with end stage renal disease. Methods: Patients’ deaths were iden-
tiﬁed from hospital lists, newspapers and referring doctors and
family members. Data relating to care during EOL were extracted
from medical records. To identify pts in whom attempts by the
Hematology unit to improve EOL care would be most relevant, pts
were considered as falling into two groups. Group (Gp) A consisted
of pts dying while under active management of the haematology
team (seen by the team within 3 mos of death and dying from their
haematological malignancy) and Gp B, pts not seen within 3
months of death, or dying of an unrelated cause. As a pilot study to
evaluate the H-QODA, a random sample of 16 pts from Gp A were
studied more extensively. Five domains were analysed & scored: 1)
pain during last week of life; 2) non pain symptoms during last
week of life; 3) advance care planning , 4) peace and dignity in last
week of life and; 5) time to death from the change of focus to EOL
care. Each domain was scored 0-2, from worst to best, for a
possible total score of 10 for a very high quality of dying assess-
ment. Results:During the study period (1 Jul 04 to 30 Jun 05), 211
pts died as part of the management of approximately 3000 pts by
the unit. Of the 211 pts who had died, 98 were in Gp A and 113 in
Gp B. Thirteen pts died who had received HSCT, 2 from alloge-
neic donors and 11 autologous. In preliminary analyses, pts in Gp
A were signiﬁcantly younger (71.5 vs 75yrs) than Gp B (p0.04),
and had a greater proportion of aggressive diagnoses (acute leu-
kaemia, multiple myeloma and NHL) (p0.001). Twenty one
percent of pts in Gp A died in the adjacent hospice facility,
compared to 12% in GpB (p0.005). In the random sample of pts
from Gp A, the H-QODA ranged from 4 to 9 with an average of
6.5. Inter-rater reliability testing and correlation between pt, fam-
ily, disease and management factors and the H-QODA are pro-
ceeding. Conclusion: An H-QODA was developed based on do-
mains relevant at EOL. Such a tool, if validated, would be useful
for assessing impact of multidisciplinary care programs aimed at
improving EOL care.
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HYPOTHYROIDISM IN LONG-TERM SURVIVORS AFTER TBI BASED AL-
LOGENEIC STEM CELL TRANSPLANTATIONS – IMPACT OF CHRONIC
GRAFT VERSUS HOST DISEASE AND TBI DOSE
Savani, B.N.1, Shenoy, A.1, Kozanas, E.1, Wisch, L.1, Singh, A.K.2,
Childs, R.1, Barrett, A.J.1 1Hematology Branch, National Heart Lung
and Blood Institute, NIH, Bethesda, MD; 2Radiation Biology Branch,
National Cancer Institute, NIH, Bethesda, MD.
Between 09/1993 and 04/2005, 189 patients received TBI-based
allogeneic stem cell transplantation (SCT) for hematological ma-
lignancies from HLA- identical sibling. One hundred thirty four
patients (with minimum 1 year follow-up) were studied for thyroid
function at a median of 4.5 (range 1-13) years post SCT. Median
age at transplant was 36 years (range 10-55). Seventy six (57%)
received 13.6 Gy TBI with no lung shielding, 58 (43%) received 12
Gy with lung shielding (total lung dose 6Gy). Twenty-two (16.4%)
were subclinical hypothyroid (by elevation of TSH level only) and
17 (12.6%) had overt hypothyroidism at a median of 2.4 (range
1.5-4.5 years) and 2.6 (range 1.5-5 years) after SCT respectively. In
univariate analysis overt and subclinical hypothyroidism was sig-
niﬁcantly associated with age  median, TBI dose  12 Gy, and
presence of chronic GVHD: Fourteen of 75 patients with chronic
GVHD vs. 3/59 (p0.02) developed overt, and 17/75 vs. 5/59
(p0.03) developed subclinical hypothyroidism. In multivariate
analysis TBI dose 12 Gy and cGVHD were independently asso-
ciated with increased risk of overt hypothyroidism: (TBI dose
12Gy RR 2.4, p0.04; chronic GVHD RR 2.6, p0.03). TBI
dose and cGVHD were also risk factors for subclinical hypothy-
roidism (RR 3.8, p0.02 and RR 3.8 p0.02 respectively). Fifteen
patients (8 normal and 7 abnormal thyroid functions) were studied
for anti-thyroglobulin and anti-peroxidase antibodies, 7 patients
were tested positive. There was no association of occurrence of
thyroid antibodies with hypothyroidism (5/7 vs. 2 /8) nor with
cGVHD. In conclusion thyroid dysfunction is relatively common
after SCT and is more likely to occur in older patients receiving
higher TBI doses developing cGVHD. Thyroid dysfunction did
not appear to be related to a classical autoimmune process.
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A JOURNEY TO PERFORMANCE EXCELLENCE UTILIZING THE MAL-
COLM BALDRIGE MODEL IN A BONE MARROW TRANSPLANT UNIT
Schriber, J.P.1,2, Majkowski, G.O.1, Kendrick, S.1, Simpson, E.1,
Sarkodee-Adoo, C.1,2, Briggs, A.D.1,2, Forman, S.J.1,2,
Alvarnas, J.C.1,2 1City of Hope Banner BMT Unit, Phoenix, AZ; 2City
of Hope, Duarte, CA.
Continuous quality improvement is critical for organizations as they
strive to provide performance excellence. The Baldrige award used to
recognize role model behaviors is the highest achievement in the
United States for business and service excellence. Health care cur-
rently comprises over half of all applicants. The approach is unique in
that it is not prescriptive, rather it provides a framework for the
description of what the applicant does, how they perform this service
and how well they compare to others providing similar services.
Although few win, applying forces the applicant to examine how they
perform core services using 6 broad categories: Leadership, Strategic
Planning, Customer Service, Information management, Human Re-
source Focus and Process management. For each a results section
evaluates how well you perform relative to your competition. Such an
approach is well suited to transplant centers. To prepare our applica-
tion we divided into groups focusing on each core area to prepare
answers to the criteria questions addressing issues such as ethics,
employee and client satisfaction. These were reviewed by senior lead-
ership to create the ﬁnal document. As we prepared opportunities for
improvement (OFIs) were identiﬁed, new processes and correspond-
ing measurement tools were developed. Even before submission this
allowed our program to reﬁne and align strategic goals and integrate
these throughout the entire BMT team. It also signiﬁcantly enhanced
team building by providing an atmosphere of ownership. For some
organizations self assessment may be sufﬁcient. Programs who for-
mally apply are evaluated by specially trained examiners who provide
feedback on strengths and OFIs based on the criterion outlined in the
application. Programs who move forward to consensus or site visit
receive feedback at the highest level achieved. Importantly the feed-
back does not suggest how to improve but rather highlights areas that
may not have been addressed and why they are important to achieving
your goals. The program determines how best to address these gaps.
As a result of our feedback some changes we implemented included
modifying the leadership structure, developing a formal strategic plan,
new surveys to capture referring physician satisfaction and prefer-
ences. Using the Baldrige model aligns leaders, provides focus to
organizational priorities and gives an outside perspective measured
against other similar high performing organizations.
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A SURVEY OF HEMATOPOIETIC CELL TRANSPLANT SURVIVORS AND
SPOUSES: WHAT ARE THE MAJOR ISSUES OF CONCERN POST-TRANS-
PLANT?
Stewart, S.K.1 1Blood & Marrow Transplant Information Network,
Highland Park, IL.
Between July 19 and October 1 2006, BMT InfoNet conducted
an online survey to identify issues of concern to HSCT survivors
and their families. Five hundred and thirty eight people completed
the survey including 369 survivors, 63 survivor spouses, and 74
parents.
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Thirty-ﬁve percent of survivors were transplanted with related
donor cells, 25% with unrelated donor cells, and 40 percent had an
autologous transplant. Age at time of transplant ranged from 6
months to 69 years. Median age was 42.
The year of the survivor’s most recent transplant ranged from
1981 to 2006 with a median of 2002. Sixty-three of the respondents
had two or more transplants.
Issues of concer, rating by frequency with which they were cited,
are shown in Table 1.
Psychological health of the survivor (71%), monitoring long-
term complications (70%), chronic GVHD (74% allogeneic relat-
ed-donor transplant, 81% allogeneic unrelated-donor transplant)
and fatigue (66%) were the top issues cited by survivors. Other
major concerns were cognitive problems (49%), psychological
health of the family (47%), educating local doctors about long-
term follow-up care (43%), health insurance (42%), secondary
cancers (42%) and sexuality (41%).
Spouses expressed greater concern than survivors about ﬁnancial
problems (43% vs. 30%), psychological health of the family (59% vs.
47%), and caregiver burnout (44% vs. 29%). Survivors had greater
concern than spouses about cognitive problems (49% vs. 37%), sec-
ondary cancers (42% vs. 24%) and infertility (22% vs. 8%).
Spouses of survivors who were transplanted with unrelated donor
cells expressed concern more frequently than other spouses about
the psychological health of the survivor, fatigue, psychological
health of the family, and marital difﬁculties.
Ninety-one percent of respondents said they would be interested
in an educational forum to help them cope with survivorship issues.
The growing number of HSCT survivors requires a fresh look at
how to equip patients and families to live well post-transplant. The
results of this survey have been used to design of a one-day
Transplant Survivors Symposium, April 14, 2007 in Chicago IL.
Between 200 and 300 survivors and their families are expected to
attend. Symposium proceedings will be available to non-partici-
pants via the web, on CD, and in print.
Issues of Concern to HSCT Survivors and Spouses
Issue Survivors Spouses
Psychological Health of Survivor 71% 78%
Monitoring Long Term
Complications 70% 67%
Fatigue 66% 70%
Cognitive Problems 49% 37%
cGVHD 47% 49%
Psychological Health of Family 47% 59%
Educating Local Physicians About
Survivor Needs 43% 37%
Health Insurance 42% 44%
Secondary Cancers 42% 24%
Sexuality 41% 37%
Employment 36% 35%
Immunization 36% 30%
Life Insurance 33% 32%
Financial Problems 30% 43%
Caregiver Burnout 29% 44%
Dental Problems 26% 21%
Resume Relations w/ Family &
Friends 24% 17%
Infertility 22% 8%
Complementary/Alternative
Medicine 20% 13%
Marital Difficulties 20% 25%
Pain Control 19% 24%
Young Adult Issues 7% 5%
Sibling Needs 5% 3%
Behavioral Problems 2% 3%
Delayed Growth 1% 2%
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P53 MUTATIONS IN SECONDARY MALIGNANCIES AFTER ALLOGENEIC
HEMATOPOIETIC CELL TRANSPLANTATION
Zouvelou, C.2, Bertz, H.2, Faber, P.2, Finke, J.2, Spyridonidis, A.1
1Hematology,Patras University Medical Center, Rio-Patras, Greece;
2Hematology-Oncology, Freiburg University Medical Center, Freiburg,
Germany.
We previously demonstrated frequent genomic alterations
measured by microsatellite instability (MSI) in non-malignant
and malignant epithelial tissues of pts who underwent aHCT
(Blood 2006;107:3389-3396). Transplant survivors have a high
risk of developing secondary cancer, especially squamous cell
carcinomas. The p53 gene plays a pivotal role in maintaining
genome integrity and in the development of cancer. We hy-
pothesized that besides the alterations in microsatellite regions
also p53 mutations occur after aHCT and may play a role in
malignant transformation and development of secondary cancer.
Therefore, we performed mutation analysis of the p53 gene on
malignant cells isolated from parafﬁn-embedded tumor biopsies
from 4 pts that developed secondary epithelial malignancies
2-12 years post aHCT and on non-neoplastic buccal cells ob-
tained from 4 otherwise healthy pts 3-5 years following aHCT.
Buccal cells from 3 healthy individuals and HaCat cells with a
known p53 heterozygous mutation were used as negative and
positive controls, respectively. DNA extraction was followed by
proofread-PCR with speciﬁc primers for the exons 5-8. Each
PCR product was cloned in a pUC vector and transfected in
Escherischia coli chemocompetent cells. Sequence analysis was
performed on 8-12 clones per exon per patient. p53 mutations
were not found in the buccal cells of the aHCT healthy recip-
ients. p53 mutations were evident in 2 out of 4 tumor specimens.
One patient with a squamous cell carcinoma developed 2 years
post aHCT was found to harbour a single p53 mutation in exon
8. This p53 mutation was evident in 10 out of the 10 clones
tested, suggesting that 100% of the malignant cells were mu-
tated. In the second patient with an underlying malignancy of
the tongue, two different mutations (exons 5 and 8) in 50% of
the isolated cells were detected. Despite the small size of the
sample (4 pts), p53 mutations seem to occur frequently (50%) in
secondary malignancies after HCT. We didn
t ﬁnd p53 muta-
tions in nonmalignant epithelial cells of the oral cavity. How-
ever, given the low sensitivity of the applied methodology (de-
tection of a mutation if it affects more than 40% of the tissue
cells) we cannot exclude that indeed p53 mutations are already
present in a lower percentage of non-neoplastic cells before
overt malignant transformation occurs. Results regarding the
presence of p53 mutations in nonmalignant tissues affected with
chronic GvHD will be presented in the meeting.
LYMPHOMA/MULTIPLE MYELOMA
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LOW DOSE THALIDOMIDE MAINTENANCE IN MYELOMA PATIENTS
AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION
Bayer, R.-L.1, John, V.1, Devoe, C.1, Cannon, M.1, Klocke, J.1,
Gissinger, D.1 1North Shore University Hospital, Manhasset, NY.
Autologous stem cell transplantation has become the gold
standard for treatment of patients with multiple myeloma under
the age of 65, and improves survival for these patients. It is
evident that all patients will progress after transplantation. At
this time it is not clear what is the best induction regimen prior
to high dose chemotherapy and ASCT. Thalidomide has been
proven to impact on plasma cell growth through multiple mech-
anisms. At our institution we used thalidomide (50-100 mg)
after ASCT as a maintenance program along with a bisphos-
phonate (Zometa or Aredia). We reviewed 68 myeloma patients
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